

**Interaction Report****Report ID:****Date Produced:** 07 December 2021**Antiretroviral Treatment****Co-medications**

Dolutegravir (DTG)

Magnesium supplements

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org).

**Description of the interactions**

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

**Dolutegravir (DTG) + Magnesium supplements**

Coadministration has not been studied. Magnesium is eliminated in kidney, mainly by glomerular filtration. Dolutegravir binds to divalent cations, such as magnesium, and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed. Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing magnesium. Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing magnesium.